“Growth Strategies and Exit Alternatives for MedTech Companies” Lessons Learned from Successful MedTech Companies Dr Richard D Gill Board Member, Launchpad Venture Group Mass Medic Meeting September 12th 2008

Background What were the obstacles to growing the business(es)? What growth strategies were pursued and why? What were the exit alternatives, and what were the key strategic decisions made that resulted in success?

Unilever, BTG, Genome Therapeutics, ActiveCyte, AnVil, Sequitur, Signet Laboratories, ProNAi, Launchpad Venture Group

Relevant Portfolio Sequitur (sold to Invitrogen) Oligo & RNAi Services & Technology Signet Laboratories (sold to Covance) Oncology & Neurodegenerative Diagnostics Catalyst Oncology (sold to Diagnocure) Colon & Breast Cancer Diagnostics Neuroptix (B Round Financing $17.5M) Alzheimer’s Disease Diagnostic Device NABsys (A Round Financing $1M) Gene Sequencing Device

Resources What were the obstacles to growing the business(es)? Financing UnderCapitalized – Fund the Froth Technical Intellectual Property – Patents, TM, Branding Regulatory – Third Party FDA Requirements Expertise Recruiting – Can Do Teams Outsourcing – Virtual Development

Revenues What growth strategies were pursued and why? Direct Sales OEM High Salary Costs OEM Sharing a Bigger Pie M&A Realize value with $$/Stock/Earn Out

Liquidity What were the exit alternatives, and what were the key strategic decisions made that resulted in success? OEM Third Party Marketing With a view to M&A M&A Provide for Capitalization With Earn Out Provisions License Least Capital Intensive

It has already happened… (Outsourcing, that is…) The large Biotechs have become Pharmas… Amgen, Genentech, Chiron, Biogen-Idec, Genzyme The Pharmas & Device & Diagnostic Companies are becoming the marketing & distribution Houses The small Biotechs & Start Ups are the R&D Innovative Shops… Backed by the Academic Research Faculty…

Its all about the IP! Without patents (intellectual property) you are nowhere You need the 20 year protection in order to protect the huge investment needed Originally patents were filed on pharmaceutical & diagnostic uses of chemicals from the paints & dyes industry Now its biology’s turn with genomics & proteomics

Market is Demanding.. Evidence Based Personalized Medicine vs Block Buster ‘One Size Fits All’ Q? But can Pharma change? A: Yes - Driven by cost escalation Pharma is changing… ‘A la Unilever Soap Powder/Liquid Detergent’

Evidence Based Medicine Hereditary – Hemophilia – BeneFIX (Wyeth) Cancer – Her2 +ve (Bayer) = Herceptin (Genentech) Diabetes – Blood Glucose +/- = Insulin What next? Alzheimer’s Diagnostic & Treatment? Personal Genomic Profile & Prognosis?

HealthCare Reform Q? Why did Hilary Clinton fail at HealthCare Reform? Easy A: Pharma lobby spent $280M+ to destroy the reform ‘Small potatoes’ Harder A: ‘Bill Clinton Walks on Water’ Real A: It was all about Gennifer Flowers

Value Proposition For the Future Knowledge Management & Interpretation of Same… Horizontal = Dx (Titrate Patients) in order to administer Rx (Effective Therapeutics) Vertical = Portable Electronic Medical Record & Portable Medical Insurance (Medicare/Medicaid & Socialized Medicine) ‘Brazilian Soldiers’

Development Opportunity ‘Drug Rescue’ Repositioning Old Drugs ‘Orphan Drugs’ less than 120,000 patients; R&D tax credits; up to 6 years of monopoly (regardless of IP) Lifestyle & Insurance Drugs….

Life Style & Insurance Drugs Life Style – Viagra It will not ever not work for the patient or the partner – bound to make $$$! Insurance – Lipitor So you weren’t ill, but you might drop dead if you stop taking it – pay premium for life!

New Use Old Drugs Cardiovascular – side effect hair growth = Rogaine

That said… Great way to make a living! You get to make $$$ & see patients successfully treated ‘Just don’t assume its about curing folks - folks!?’ Dr Richard D Gill ActiveCyte Holdings RIKI4455@aol.com 781 864 7515 Bb 269 823 8430

We all need different medicine

Questions? RIKI4455@aol.com